It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

This was the stock's second consecutive day of gains.

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

CHENNAI: Shares of Dr Reddy’s Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a ...

Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug pipeline ...

The USPTO’s Patent Trial and Appeal Board instituted Merck’s (MRK) patent grant review against Halozyme’s (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 ...

Merck wrapped up its recent trading day at $78.27, rising 1.46% and outpacing the sluggish S&P 500. The company’s stock has ...

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...